RHYTHM PHARMACEUTICALS, INC. 4

Chief Medical Officer Manher Joshi received 50,000 stock options at $115.44 and 25,000 RSUs of Rhythm Pharmaceuticals, Inc. (RYTM) as equity awards on August 17, 2026.

On August 17, 2026, Rhythm Pharmaceuticals, Inc. Chief Medical Officer Manher Joshi received an equity compensation package consisting of 50,000 stock options with an exercise price of $115.44 per share and 25,000 restricted stock units. The stock options are scheduled to vest 25% on the first anniversary of the grant date and then 6.25% quarterly thereafter, with an expiration date of August 16, 2036, while the RSUs vest in four equal annual installments of 25% each on September 1 of 2027, 2028, 2029, and 2030, contingent on continued service. Immediately after the grants, Joshi beneficially owned 50,000 options and 25,000 RSUs (represented as common stock equivalents) on a direct basis in Rhythm Pharmaceuticals, aligning his compensation and incentives with shareholders over a long-term horizon. Using the option exercise price as a proxy for the stock price, the notional value of the new option grant is approximately $5.77 million, and the RSU grant is approximately $2.89 million, implying a total equity award of roughly $8.66 million and an equivalent estimated value of his post-grant holdings.

Filing Facts

CIK

1649904

Ticker

RYTM

Form

4

Source Type

fda

Accession

0001649904-26-000020

Alert Tier

7